- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05936580
Nuwiqin annostus ja tulokset hemofiliaa sairastavien naisten/tyttöjen hoidossa, joka tarvitsee FVIII-hoitoa leikkaukseen
Nuwiqin annostus ja tulokset hemofiliaa sairastavien naisten/tyttöjen hoidossa FVIII-hoitoa tarvitseva leikkaus – kansainvälinen, avoin, kontrolloimaton tutkimus (NuDIMENSION)
Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Female patients with mild to moderate haemophilia A will often need FVIII concentrates to provide haemostatic cover during major surgery. This prospective, open-label, non-controlled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 4
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Cristina Solomon
- Puhelinnumero: +41795859042
- Sähköposti: cristina.solomon@octapharma.com
Opiskelupaikat
-
-
-
Madrid, Espanja
- Rekrytointi
- Hospital Universitario la Paz
-
Seville, Espanja
- Rekrytointi
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Catanzaro, Italia
- Rekrytointi
- Aziendo Ospedaliera "Puglieze Ciaccio"
-
Palermo, Italia
- Rekrytointi
- Policlinico "P. Giaconne"
-
-
Trentino-Alto Adige
-
Trento, Trentino-Alto Adige, Italia
- Rekrytointi
- Santa Chiara Hospital - APSS
-
-
-
-
-
Chambray-lès-Tours, Ranska
- Rekrytointi
- Avenue de la République
-
Nantes, Ranska
- Rekrytointi
- CHU de Nantes Hôtel-Dieu
-
Strasbourg, Ranska
- Rekrytointi
- Chu de Strasbourg
-
-
-
-
-
Bonn, Saksa
- Rekrytointi
- Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin
-
Duisburg, Saksa
- Rekrytointi
- Gerinnungszentrum Rhein-Ruhr
-
Hamburg, Saksa
- Rekrytointi
- Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik
-
-
-
-
-
Belgrade, Serbia
- Rekrytointi
- Clinical Center for Serbia
-
-
-
-
-
Helsinki, Suomi
- Rekrytointi
- Helsinki University Hospital,Coagulation Disorder Unit
-
-
-
-
-
Bern, Sveitsi
- Rekrytointi
- Insel Spital Bern
-
-
-
-
-
Montevideo, Uruguay
- Ei vielä rekrytointia
- Centro Hospitalario Pereira Rossell
-
-
-
-
-
Leeds, Yhdistynyt kuningaskunta
- Rekrytointi
- St. James's University Hospital
-
-
-
-
Texas
-
San Antonio, Texas, Yhdysvallat, 78229
- Rekrytointi
- UT Health San Antonio
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Women/girls with haemophilia A (FVIII:C ≥1-<40%) according to medical history. Additionally, women/girls with documented FVIII activity levels between ≥ 40% and 50% may be included if there is a documented history of clinically significant bleeding episodes consistent with haemophilia A; and/or either documented prior treatment with FVIII concentrates or a clinical indication that FVIII treatment would have been appropriate (e.g., use of FVIII from a family member, or treatment with alternative haemostatic agents due to access limitations)
- At least 12 years of age
- Scheduled to undergo major surgery* requiring FVIII treatment, including elective and emergency procedures and caesarean section in pregnant women with haemophilia A
- Freely given written informed consent of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations
Exclusion Criteria:
- Coagulation disorder other than haemophilia A
- Present or past FVIII inhibitor (≥0.6 Bethesda units [BU]/mL)
- Severe liver or kidney disease (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels >5 times the upper limit of normal; or creatinine >120 μmol/L)
- Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)
- Pregnancy, except in participants with a planned caesarean section
- Already had surgery in this study
- Current participation in another interventional clinical trial
- Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Nuwiq
All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL. |
Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F). |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Overall haemostatic efficacy
Aikaikkuna: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Overall haemostatic efficacy of treatment measured as binary "success" or "failure". The overall perioperative haemostatic efficacy of Nuwiq will be adjudicated by an Independent Data Monitoring Committee (IDMC) and determined using a composite assessment algorithm that considers the surgeon's assessment of intraoperative haemostatic efficacy and the investigator's assessment of postoperative haemostatic efficacy to classify the overall haemostatic efficacy as success or failure. |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Intraoperative haemostatic efficacy
Aikaikkuna: During surgery: From first skin incision to last suture
|
Assessment of intraoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: Intraoperative blood loss was lower than or equal to the average expected blood loss for the type of procedure performed in a patient with normal haemostasis and of the same sex, age, and stature Good: Intraoperative blood loss was higher than the average expected blood loss but lower or equal to the maximal expected blood loss for the type of procedure in a patient with normal haemostasis. Moderate: Intraoperative blood loss was higher than the maximum expected blood loss for the type of procedure performed in a patient with normal haemostasis, but haemostasis was controlled. None: Haemostasis was uncontrolled, necessitating a change in the clotting factor replacement regimen. |
During surgery: From first skin incision to last suture
|
|
Postoperative haemostatic efficacy
Aikaikkuna: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Assessment of postoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: No postoperative bleeding or oozing that was not due to complications of surgery. All postoperative bleeding (due to complications of surgery) was controlled with Nuwiq as anticipated for the type of procedure. Good: No postoperative bleeding or oozing that was not due to complications of surgery. Control of postoperative bleeding due to complications of surgery required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. Moderate: Some postoperative bleeding and oozing that was not due to complications of surgery. Control of postoperative bleeding required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. None: Extensive uncontrolled postoperative bleeding and oozing. |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
|
Allogenic blood products
Aikaikkuna: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Use of allogeneic blood products (red blood cells, platelets, and other blood products) |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
|
FVIII plasma levels
Aikaikkuna: ≤30 minutes before and 15-30 minutes after Nuwiq injection
|
Perioperative plasma levels |
≤30 minutes before and 15-30 minutes after Nuwiq injection
|
|
Perioperative haemostatic efficacy per WFH criteria
Aikaikkuna: ≤30 minutes before and 15-30 minutes after Nuwiq injection
|
Assessed using 4-point scale recommended by WFH: Excellent: Intra- and post-operative blood loss similar to non-haemophilic patient. No extra doses of FVIII/bypassing agents needed Good: Intra- and/or post-operative blood loss slightly increased over expectation for non-haemophilic patient, but judged to be clinically insignificant. No extra doses of FVIII/bypassing agents needed Fair: Intra- and/or post-operative blood loss increased over expectation for the non-haemophilic patient, and additional treatment needed. Extra dose of FVIII/bypassing agents needed, or increased blood component of anticipated transfusion requirement Poor: Significant intra- and/or post-operative blood loss substantially increased over expectation for non-haemophilic patient, requires intervention not explained by medical issue other than haemophilia. Unexpected hypotension, unexpected transfer to ICU due to bleeding, substantially increased blood component of the anticipated transfusion requirement |
≤30 minutes before and 15-30 minutes after Nuwiq injection
|
|
Adverse events
Aikaikkuna: From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of adverse events recorded during the full study period |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
|
Thrombotic events
Aikaikkuna: From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of thrombotic events during the study |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
|
FVIII inhibitor formation
Aikaikkuna: From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of FVIII inhibitor formation |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Johannes Oldenburg, Experimental Haematology and Transfusion Medicine, University Clinic Bonn
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Geneettiset sairaudet, synnynnäiset
- Hematologiset sairaudet
- Veren hyytymishäiriöt
- Hemorragiset häiriöt
- Veren hyytymishäiriöt, perinnölliset
- Koagulaatioproteiinien häiriöt
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Hemic- ja imusuutteet
- Hemofilia A
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Biologiset tekijät
- Veriproteiinit
- Veren hyytymistekijät
- Proteiinin esiasteet
- Tekijä VIII
Muut tutkimustunnusnumerot
- GENA-23
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .